FOXO4-DRI vs GDF-11
A side-by-side research comparison of FOXO4-DRI and GDF-11 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | GDF-11 |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Growth Differentiation Factor 11 |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Signals through activin type II receptors and SMAD2/3 to restore stem cell function, promote neurogenesis, and improve vascular remodeling in the context of aging. |
| Molecular weight | ~4,500 Da | 12,500 Da |
| Half-life | 12-24 hours (D-amino acid stability) | 6-8 hours |
| Bioavailability | Moderate (SubQ) | Moderate (SubQ/IV) |
| Typical dose | 5-10 mg/kg (animal studies) | 0.1-0.5 mg/kg (research) |
| Frequency | 3x per week for 3 weeks | Daily (animal studies) |
| Route | Subcutaneous | Subcutaneous |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
GDF-11 reported benefits
- Potential tissue rejuvenation
- Neurogenesis stimulation
- Cardiac hypertrophy reversal
- Muscle stem cell activation
- Vascular remodeling
Related comparisons
Research and educational reference only. Not medical advice.